Lonza Publishes Restated Financials for 2018

• Lonza reports restated 2018 financials for sales, CORE EBITDA and CORE EBIT

Basel, Switzerland, 20 June 2019 – As a pre-information for the reporting of the Half-Year Results 2019 on 24 July 2019, Lonza today is providing restated financials to reflect historically its newly aligned segment structure for the Half-Year 2018 and the Full-Year 2018 reporting periods.

On 25 February 2019, Lonza announced the alignment of its two segments: Lonza Pharma & Biotech and Lonza Specialty Ingredients. The new segment structure as of 1 March 2019 is as follows:

The Pharma Biotech & Nutrition (LPBN) segment consists of CDMO services for biologics (large molecules and cell & gene technologies) and chemicals (small molecules) and product-related businesses of Bioscience Solutions and Consumer Health and Nutrition. The Specialty Ingredients (LSI) segment consists of Consumer & Resources Protection and Consumer Product Ingredients. As communicated previously, the former Consumer Health business within LSI was split; and the business for nutritional ingredients, dosage form and delivery systems for the consumer health markets moved into LPBN.

The restated financials for 2018 for LPBN and LSI are provided for sales, CORE EBITDA and CORE EBIT. The restatement also takes into account that Lonza completed the divestment of its Water Care business, formerly part of LSI, on 28 February 2019. The business was reported as discontinued operation in 2018 and will be consistently presented in 2019.

For Lonza Restated Financials 2018, click one of the following links:

2018 Restated Financials PDF

2018 Restated Financials XLS

News Release PDF

2018 Restated Financials Report PDF

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum^®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.

Lonza Contact Details

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Privacy Policy link